How I treat sinusoidal obstruction syndrome

Blood

Volumn 123, Issue 26, 2014, Pages 4023-4026

  Chao, Nelson ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DIURETIC AGENT; GEMTUZUMAB OZOGAMICIN; HEPARIN; METHOTREXATE; NARCOTIC ANALGESIC AGENT; RAPAMYCIN; TACROLIMUS; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASCITES; CANCER PATIENT; CASE REPORT; CLINICAL EVALUATION; COMPASSIONATE USE; DIARRHEA; DIURETIC THERAPY; DOPPLER ECHOGRAPHY; ECHOGRAPHY; EDEMA; ERYTHEMA; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL ENDOSCOPY; GRAFT VERSUS HOST REACTION; HEPATOMEGALY; HUMAN; INDUCTION CHEMOTHERAPY; INTESTINE; LABORATORY TEST; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT INDICATION; UPPER GASTROINTESTINAL TRACT; WEIGHT GAIN;

ALLOGRAFTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS;

EID: 84903642515     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-551630     Document Type: Article

References (61)

1. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984;4(1):116-122. (Pubitemid 14185436)
2. Zeniya M, Fukata H, Toda G. Thrombomodulin expression of sinusoidal endothelial cells in chronic viral hepatitis. J Gastroenterol Hepatol. 1995;10(Suppl 1):S77-S80.
3. Scoazec JY, Feldmann G. In situ immunophenotyping study of endothelial cells of the human hepatic sinusoid: results and functional implications. Hepatology. 1991;14(5):789-797.
4. Volpes R, van den Oord JJ, Desmet VJ. Distribution of the VLA family of integrins in normal and pathological human liver tissue. Gastroenterology. 1991;101(1):200-206.
5. Shulman HM, Gown AM, Nugent DJ. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol. 1987;127(3): 549-558. (Pubitemid 17089816)
6. Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB. Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology. 1994;19(5):1171-1181.
7. Tabbara IA, Ghazal CD, Ghazal HH. Early drop in protein C and antithrombin III is a predictor for the development of veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation. J Hematother. 1996;5(1):79-84.
8. Salat C, Holler E, Kolb HJ, et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood. 1997;89(6):2184-2188. (Pubitemid 27132137)
9. Faioni EM, Krachmalnicoff A, Bearman SI, et al. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver. Blood. 1993;81(12):3458-3462. (Pubitemid 23172934)
10. Scrobohaci ML, Drouet L, Monem-Mansi A, et al. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res. 1991;63(5):509-519.
11. Iguchi A, Kobayashi R, Kaneda M, Kobayashi K. Plasma protein C is a useful clinical marker for hepatic veno-occlusive disease (VOD) in stem cell transplantation. Pediatr Blood Cancer. 2010; 54(3):437-443.
12. Attal M, Huguet F, Rubie H, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood. 1992;79(11):2834-2840.
13. Rosenthal J, Sender L, Secola R, et al. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Bone Marrow Transplant. 1996;18(1):185-191. (Pubitemid 26289652)
14. Marsa-Vila L, Gorin NC, Laporte JP, et al. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. Eur J Haematol. 1991; 47(5):346-354.
15. Or R, Nagler A, Shpilberg O, et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation. 1996; 61(7):1067-1071. (Pubitemid 26120257)
16. Tay J, Tinmouth A, Fergusson D, Huebsch L, Allan DS. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(2):206-217. (Pubitemid 46115719)
17. Essell JH, Thompson JM, Harman GS, et al. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 1992;10(4):367-372.
18. Essell JH, Schroeder MT, Harman GS, et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998; 128(12 Pt 1):975-981. (Pubitemid 28275173)
19. Chalandon Y, Roosnek E, Mermillod B, et al. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2004;10(5):347-354. (Pubitemid 38519573)
20. Dignan F, Gujral D, Ethell M, et al. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease. Bone Marrow Transplant. 2007;40(1):79-82. (Pubitemid 47018417)
21. Cappelli B, Chiesa R, Evangelio C, et al. Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan. Br J Haematol. 2009; 147(4):554-560.
22. Corbacioglu S, Cesaro S, Faraci M, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012; 379(9823):1301-1309.
23. Fisher DC, Vredenburgh JJ, Petros WP, et al. Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver. Bone Marrow Transplant. 1998;21(2): 117-122. (Pubitemid 28044002)
24. Brown SA, Goringe A, Fegan C, et al. Parenteral glutamine protects hepatic function during bone marrow transplantation. Bone Marrow Transplant. 1998;22(3):281-284. (Pubitemid 28382994)
25. Dignan FL, Wynn RF, Hadzic N, et al; Haematooncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation. BCSH/ BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol. 2013;163(4): 444-457.
26. Lee SH, Yoo KH, Sung KW, et al. Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Bone Marrow Transplant. 2010; 45(8):1287-1293.
27. El-Sayed MH, El-Haddad A, Fahmy OA, Salama II, Mahmoud HK. Liver disease is a major cause of mortality following allogeneic bone-marrow transplantation. Eur J Gastroenterol Hepatol. 2004;16(12):1347-1354. (Pubitemid 39627537)
28. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996;17(2):225-230. (Pubitemid 26057312)
29. Dulley FL, Kanfer EJ, Appelbaum FR, et al. Venocclusive disease of the liver after chemoradiotherapy and autologous bone marrow transplantation. Transplantation. 1987;43(6): 870-873. (Pubitemid 17084267)
30. Reed EC, Myerson D, Corey L, Meyers JD. Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen. Blood. 1991;77(1):195-200.
31. Lau GK, Lok AS, Liang RH, et al. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology. 1997;25(6):1497-1501. (Pubitemid 27250775)
32. Frickhofen N, Wiesneth M, Jainta C, et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood. 1994;83(7): 1998-2004.
33. Strasser SI, Myerson D, Spurgeon CL, et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology. 1999;29(6):1893-1899. (Pubitemid 29247066)
34. Rodriguez-Iñigo E, Tomás JF, Gómez-García de Soria V, et al. Hepatitis C and G virus infection and liver dysfunction after allogeneic bone marrow transplantation: results from a prospective study. Blood. 1997;90(3):1326-1331.
35. Locasciulli A, Bacigalupo A, VanLint MT, et al. Hepatitis C virus infection and liver failure in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995; 16(3):407-411.
36. Norol F, Roche B, Girardin MF, et al. Hepatitis C virus infection and allogeneic bone marrow transplantation. Transplantation. 1994;57(3): 393-397. (Pubitemid 24086037)
37. Locasciulli A, Testa M, Pontisso P, et al. Hepatitis C virus genotypes and liver disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997; 19(3):237-240. (Pubitemid 27077479)
38. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990;76(9):1867-1871.
39. Deeg HJ, Sullivan KM, Buckner CD, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. Bone Marrow Transplant. 1986;1(2):151-157.
40. Girinsky T, Benhamou E, Bourhis JH, et al. Prospective randomized comparison of singledose versus hyperfractionated total-body irradiation in patients with hematologic malignancies. J Clin Oncol. 2000;18(5):981-986. (Pubitemid 30123773)
41. Marsh JC. Hepatic vascular toxicity of dacarbazine (DTIC): not a rare complication. Hepatology. 1989;9(5):790-792.
42. Morgan M, Dodds A, Atkinson K, Szer J, Downs K, Biggs J. The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Haematol. 1991;77(4):529-534.
43. Lee JH, Choi SJ, Lee JH, et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol. 2005;84(5):321-330.
44. Sharafuddin MJ, Foshager MC, Steinbuch M, Weisdorf DJ, Hunter DW. Sonographic findings in bone marrow transplant patients with symptomatic hepatic veno-occlusive disease. J Ultrasound Med. 1997;16(9):575-586. (Pubitemid 27494577)
45. Herbetko J, Grigg AP, Buckley AR, Phillips GL. Veno-occlusive liver disease after bone marrow transplantation: findings at duplex sonography. AJR Am J Roentgenol. 1992;158(5):1001-1005.
46. Teefey SA, Brink JA, Borson RA, Middleton WD. Diagnosis of veno-occlusive disease of the liver after bone marrow transplantation: value of duplex sonography. AJR Am J Roentgenol. 1995;164(6): 1397-1401.
47. Pai RK, van Besien K, Hart J, Artz AS, O'Donnell PH. Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. Leuk Lymphoma. 2012;53(8):1552-1557.
48. Shulman HM, Gooley T, Dudley MD, et al. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation. 1995;59(7): 1015-1022.
49. Ho GT, Parker A, MacKenzie JF, Morris AJ, Stanley AJ. Abnormal liver function tests following bone marrow transplantation: aetiology and role of liver biopsy. Eur J Gastroenterol Hepatol. 2004; 16(2):157-162. (Pubitemid 39049651)
50. Carreras E, Grañena A, Navasa M, et al. On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease. Ann Hematol. 1993;66(2):77-80. (Pubitemid 23079672)
51. Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB. Veno-occlusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol. 1993;11(9): 1729-1736. (Pubitemid 23277325)
52. Benimetskaya L, Wu S, Voskresenskiy AM, et al. Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood. 2008; 112(10):4343-4352.
53. Evangelista V, Piccardoni P, de Gaetano G, Cerletti C. Defibrotide inhibits platelet activation by cathepsin G released from stimulated polymorphonuclear leukocytes. Thromb Haemost. 1992;67(6):660-664.
54. Berti F, Rossoni G, Biasi G, Buschi A, Mandelli V, Tondo C. Defibrotide, by enhancing prostacyclin generation, prevents endothelin-1 induced contraction in human saphenous veins. Prostaglandins. 1990;40(4):337-350. (Pubitemid 20337225)
55. Bacher P, Kindel G, Walenga JM, Fareed J. Modulation of endothelial and platelet function by a polydeoxyribonucleotide derived drug " defibrotide". A dual mechanism in the control of vascular pathology. Thromb Res. 1993;70(4): 343-348. (Pubitemid 23168840)
56. Zhou Q, Chu X, Ruan C. Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb Haemost. 1994;71(4): 507-510. (Pubitemid 24100679)
57. Richardson PG, Elias AD, Krishnan A, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998;92(3):737-744. (Pubitemid 28355454)
58. Chopra R, Eaton JD, Grassi A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionateuse study. Br J Haematol. 2000;111(4): 1122-1129. (Pubitemid 32104928)
59. Richardson PG, Murakami C, Jin Z, et al. Multiinstitutional use of defibrotide in 88 patients after stem cell transplantation with severe venoocclusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002;100(13):4337-4343. (Pubitemid 35429671)
60. Richardson PG, Soiffer R, Antin JH, et al. Defibrotide (DF) appears effective and safe in a phase II, randomized study of patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT). [abstract] Blood. 2002; 100:112a.
61. Corbacioglu S, Greil J, Peters C, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant. 2004; 33(2):189-195. (Pubitemid 38180932)